AimsTo evaluate the effect of rosuvastatin on oxidised lowdensity lipoprotein/beta2-glycoprotein I (oxLDL/β 2 GPI) complex concentration in type 2 diabetes mellitus. Methods Open label 2:1 assignment of consecutive diabetic patients into oral rosuvastatin (10 mg daily for six weeks) arm or observational arm with measurements of serum oxLDL/ β 2 GPI complexes, nitric oxide metabolites, asymmetric dimethyl arginine, nitrotyrosine alongside routine biochemistry at baseline and end of study in all patients. ResultsAfter rosuvastatin treatment the mean serum concentration of oxLDL/β 2 GPI decreased from 0.79±0.49 units/mL to 0.53±0.36 units/mL (p<0.001). The decrease was statistically independent from the decrements of mean cholesterol, LDL and triglyceride concentrations (p<0.001) but probably dependent on the decrement of nitrate (p<0.001). ConclusionIn type 2 diabetes, treatment with rosuvastatin was associated with a significant reduction of serum concentrations of oxLDL/β 2 GPI complexes, which is in further support of the already proposed effects of the drug on the oxidative metabolism of lipids and/or LDL. The oxLDL/β 2 GPI complex may represent a surrogate marker of oxidative stress in type 2 diabetes.Br J Diabetes Vasc Dis 2010;10:292-299.